$ARBE
Arbe Robotics Ltd. Stock $arbe

$arbe Overview Financials Valuation SEC Filings Company Website

2023 Q1 Form 20-F Financial Statement

#000121390023022143 Filed on March 22, 2023

Income Statement

Concept	2023 Q1	2022 Q4	2022
Revenue	$355.0K	$149.0K	$3.517M
YoY Change	-59.47%	-93.37%	56.38%
Cost Of Revenue	$316.0K	$217.0K	$1.283M
YoY Change	-17.71%	-84.93%	-10.9%
Gross Profit	$39.00K	-$68.00K	$2.234M
YoY Change	-92.07%	-108.41%	176.14%
Gross Profit Margin	10.99%	-45.64%	63.52%
Selling, General & Admin	$2.554M	$3.220M	$13.23M
YoY Change	-23.23%	-41.7%	139.62%
% of Gross Profit	6548.72%		592.39%
Research & Development	$8.124M	$10.83M	$36.73M
YoY Change	4.11%	-62.1%	28.59%
% of Gross Profit	20830.77%		1644.18%
Depreciation & Amortization	$137.0K	$132.0K	$481.0K
YoY Change	30.48%	-31.61%	40.64%
% of Gross Profit	351.28%		21.53%
Operating Expenses	$10.68M	$14.05M	$49.97M
YoY Change	-4.06%	-58.79%	46.58%
Operating Profit	-$10.64M	-$14.11M	-$47.73M
YoY Change	0.01%	-57.58%	43.43%
Interest Expense	$732.0K	$3.004M	$7.237M
YoY Change	-73.69%	-112.11%	-129.16%
% of Operating Profit
Other Income/Expense, Net			$7.237M
YoY Change			-129.16%
Pretax Income	-$9.907M	-$11.11M	$40.49M
YoY Change	26.11%	-80.87%	-169.71%
Income Tax
% Of Pretax Income
Net Earnings	-$9.907M	-$11.11M	-$40.49M
YoY Change	26.11%	-80.87%	-30.29%
Net Earnings / Revenue	-2790.7%	-7457.05%	-1151.38%
Basic Earnings Per Share			-$0.64
Diluted Earnings Per Share	-$0.15	-$0.13	-$0.80
COMMON SHARES
Basic Shares Outstanding	64.85M shares		68.49M shares
Diluted Shares Outstanding			60.96M shares

Balance Sheet

Concept	2023 Q1	2022 Q4	2022
SHORT-TERM ASSETS
Cash & Short-Term Investments	$44.90M	$54.57M	$54.57M
YoY Change	-48.77%	-45.87%	-45.87%
Cash & Equivalents	$44.90M	$54.17M	$54.17M
Short-Term Investments	$0.00	$400.0K	$400.0K
Other Short-Term Assets	$1.800M	$1.983M	$1.664M
YoY Change	-48.99%	-37.7%	-42.18%
Inventory
Prepaid Expenses
Receivables	$2.088M	$2.202M	$2.202M
Other Receivables	$0.00	$0.00	$319.0K
Total Short-Term Assets	$48.79M	$58.76M	$58.76M
YoY Change	-46.87%	-43.6%	-43.6%
LONG-TERM ASSETS
Property, Plant & Equipment	$2.026M	$1.609M	$2.074M
YoY Change	-4.12%	38.11%	78.03%
Goodwill
YoY Change
Intangibles
YoY Change
Long-Term Investments
YoY Change
Other Assets
YoY Change
Total Long-Term Assets	$2.026M	$2.074M	$2.074M
YoY Change	-4.12%	78.03%	78.03%
TOTAL ASSETS
Total Short-Term Assets	$48.79M	$58.76M	$58.76M
Total Long-Term Assets	$2.026M	$2.074M	$2.074M
Total Assets	$50.82M	$60.83M	$60.83M
YoY Change	-45.91%	-42.26%	-42.26%
SHORT-TERM LIABILITIES
YoY Change
Accounts Payable	$2.145M	$1.244M	$1.244M
YoY Change	51.91%	-37.96%	-37.96%
Accrued Expenses	$4.998M	$8.834M	$8.834M
YoY Change	-12.67%	12.97%	12.97%
Deferred Revenue
YoY Change
Short-Term Debt	$0.00		$0.00
YoY Change	-100.0%		-100.0%
Long-Term Debt Due
YoY Change
Total Short-Term Liabilities	$7.494M	$10.43M	$10.43M
YoY Change	-42.04%	-32.57%	-32.57%
LONG-TERM LIABILITIES
Long-Term Debt	$0.00	$0.00	$0.00
YoY Change
Other Long-Term Liabilities	$1.811M	$1.648M	$1.648M
YoY Change	-74.49%	-83.61%	-83.61%
Total Long-Term Liabilities	$1.811M	$1.648M	$1.648M
YoY Change	-74.49%	-83.61%	-83.61%
TOTAL LIABILITIES
Total Short-Term Liabilities	$7.494M	$10.43M	$10.43M
Total Long-Term Liabilities	$1.811M	$1.648M	$1.648M
Total Liabilities	$9.305M	$12.08M	$12.08M
YoY Change	-53.54%	-52.68%	-52.68%
SHAREHOLDERS EQUITY
Retained Earnings		-$160.1M
YoY Change		33.84%
Common Stock		$0.00
YoY Change
Preferred Stock
YoY Change
Treasury Stock (at cost)
YoY Change
Treasury Stock Shares
Shareholders Equity	$41.51M	$48.75M	$48.75M
YoY Change
Total Liabilities & Shareholders Equity	$50.82M	$60.83M	$60.83M
YoY Change	-45.91%	-42.26%	-42.26%

Cashflow Statement

Concept	2023 Q1	2022 Q4	2022
OPERATING ACTIVITIES
Net Income	-$9.907M	-$11.11M	-$40.49M
YoY Change	26.11%	-80.87%	-30.29%
Depreciation, Depletion And Amortization	$137.0K	$132.0K	$481.0K
YoY Change	30.48%	-31.61%	40.64%
Cash From Operating Activities	-$10.19M	-$8.711M	-$40.36M
YoY Change	-21.67%	-50.78%	52.79%
INVESTING ACTIVITIES
Capital Expenditures	$53.00K	$342.0K	$918.0K
YoY Change	-121.9%	-199.42%	-217.09%
Acquisitions
YoY Change
Other Investing Activities	$400.0K	$0.00	-$400.0K
YoY Change	-200.0%	-100.0%	-500.0%
Cash From Investing Activities	$347.0K	-$342.0K	-$1.318M
YoY Change	-154.05%	-120.65%	92.69%
FINANCING ACTIVITIES
Cash Dividend Paid
YoY Change
Common Stock Issuance & Retirement, Net
YoY Change
Debt Paid & Issued, Net
YoY Change
Cash From Financing Activities	561.0K	13.00K	-$4.941M
YoY Change	484.38%	-99.99%	-103.95%
NET CHANGE
Cash From Operating Activities	-10.19M	-8.711M	-$40.36M
Cash From Investing Activities	347.0K	-342.0K	-$1.318M
Cash From Financing Activities	561.0K	13.00K	-$4.941M
Net Change In Cash	-9.277M	-9.040M	-$45.43M
YoY Change	-31.53%	-109.41%	-146.37%
FREE CASH FLOW
Cash From Operating Activities	-$10.19M	-$8.711M	-$40.36M
Capital Expenditures	$53.00K	$342.0K	$918.0K
Free Cash Flow	-$10.24M	-$9.053M	-$41.28M
YoY Change	-19.77%	-47.83%	61.05%

Facts In Submission

Frame	Concept Type	Concept / XBRL Key	Value	Unit
CY2022	dei	Document Type DocumentType	20-F
CY2022	dei	Document Registration Statement DocumentRegistrationStatement	false
CY2022	dei	Document Annual Report DocumentAnnualReport	true
CY2022	dei	Document Period End Date DocumentPeriodEndDate	2022-12-31
CY2022	dei	Current Fiscal Year End Date CurrentFiscalYearEndDate	--12-31
CY2022	dei	Document Fiscal Year Focus DocumentFiscalYearFocus	2022
CY2022	dei	Document Transition Report DocumentTransitionReport	false
CY2022	dei	Document Shell Company Report DocumentShellCompanyReport	false
CY2022	dei	Entity File Number EntityFileNumber	001-40884
CY2022	dei	Entity Registrant Name EntityRegistrantName	Arbe Robotics Ltd.
CY2022	dei	Entity Incorporation State Country Code EntityIncorporationStateCountryCode	L3
CY2022	dei	Entity Address Address Line1 EntityAddressAddressLine1	107 HaHashmonaim St
CY2022	dei	Entity Address City Or Town EntityAddressCityOrTown	Tel Aviv-Yafo
CY2022	dei	Entity Address Country EntityAddressCountry	IL
CY2022	dei	Security12b Title Security12bTitle	Ordinary shares, par value NIS 0.000216 per share
CY2022	dei	Trading Symbol TradingSymbol	ARBE
CY2022	dei	Security Exchange Name SecurityExchangeName	NASDAQ
CY2023Q1	dei	Entity Common Stock Shares Outstanding EntityCommonStockSharesOutstanding	64848021	shares
CY2022	dei	Entity Well Known Seasoned Issuer EntityWellKnownSeasonedIssuer	No
CY2022	dei	Entity Voluntary Filers EntityVoluntaryFilers	No
CY2022	dei	Entity Current Reporting Status EntityCurrentReportingStatus	Yes
CY2022	dei	Entity Interactive Data Current EntityInteractiveDataCurrent	Yes
CY2022	dei	Entity Filer Category EntityFilerCategory	Non-accelerated Filer
CY2022	dei	Entity Emerging Growth Company EntityEmergingGrowthCompany	true
CY2022	dei	Entity Ex Transition Period EntityExTransitionPeriod	false
CY2022	dei	Icfr Auditor Attestation Flag IcfrAuditorAttestationFlag	false
CY2022	dei	Document Accounting Standard DocumentAccountingStandard	U.S. GAAP
CY2022	dei	Entity Shell Company EntityShellCompany	false
CY2022	dei	Auditor Firm AuditorFirmId	1057
CY2022	dei	Auditor Name AuditorName	Somekh Chaikin
CY2022	dei	Auditor Location AuditorLocation	Israel
CY2022Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	54171000	usd
CY2021Q4	us-gaap	Cash And Cash Equivalents At Carrying Value CashAndCashEquivalentsAtCarryingValue	100811000	usd
CY2022Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	144000	usd
CY2021Q4	us-gaap	Restricted Cash Current RestrictedCashCurrent	125000	usd
CY2022Q4	us-gaap	Short Term Investments ShortTermInvestments	400000	usd
CY2022Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	2202000	usd
CY2021Q4	us-gaap	Accounts Receivable Net Current AccountsReceivableNetCurrent	187000	usd
CY2022Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	1839000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets Current PrepaidExpenseAndOtherAssetsCurrent	3058000	usd
CY2022Q4	us-gaap	Assets Current AssetsCurrent	58756000	usd
CY2021Q4	us-gaap	Assets Current AssetsCurrent	104181000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	465000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1609000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Net PropertyPlantAndEquipmentNet	1165000	usd
CY2022Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	2074000	usd
CY2021Q4	us-gaap	Assets Noncurrent AssetsNoncurrent	1165000	usd
CY2022Q4	us-gaap	Assets Assets	60830000	usd
CY2021Q4	us-gaap	Assets Assets	105346000	usd
CY2021Q4	us-gaap	Short Term Borrowings ShortTermBorrowings	4916000	usd
CY2022Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	1244000	usd
CY2021Q4	us-gaap	Accounts Payable Trade Current AccountsPayableTradeCurrent	2005000	usd
CY2022Q4	us-gaap	Operating Lease Liability Current OperatingLeaseLiabilityCurrent	364000	usd
CY2022Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	2861000	usd
CY2021Q4	us-gaap	Employee Related Liabilities Current EmployeeRelatedLiabilitiesCurrent	3095000	usd
CY2022Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	351000	usd
CY2021Q4	us-gaap	Deferred Revenue Current DeferredRevenueCurrent	726000	usd
CY2022Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	5609000	usd
CY2021Q4	us-gaap	Accounts Payable And Other Accrued Liabilities Current AccountsPayableAndOtherAccruedLiabilitiesCurrent	4725000	usd
CY2022Q4	us-gaap	Liabilities Current LiabilitiesCurrent	10429000	usd
CY2021Q4	us-gaap	Liabilities Current LiabilitiesCurrent	15467000	usd
CY2022Q4	arbe	Warrants To Purchase Series B2 Preferred Shares WarrantsToPurchaseSeriesB2PreferredShares	17000	usd
CY2022Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	1631000	usd
CY2021Q4	us-gaap	Derivative Liabilities Noncurrent DerivativeLiabilitiesNoncurrent	10056000	usd
CY2022Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	1648000	usd
CY2021Q4	us-gaap	Liabilities Noncurrent LiabilitiesNoncurrent	10056000	usd
CY2022Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000216
CY2021Q4	us-gaap	Common Stock Par Or Stated Value Per Share CommonStockParOrStatedValuePerShare	0.000216
CY2022Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2021Q4	us-gaap	Common Stock Shares Authorized CommonStockSharesAuthorized	130000000	shares
CY2022Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	64160890	shares
CY2021Q4	us-gaap	Common Stock Shares Outstanding CommonStockSharesOutstanding	63016856	shares
CY2022Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	208893000	usd
CY2021Q4	us-gaap	Additional Paid In Capital AdditionalPaidInCapital	199469000	usd
CY2022Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-160140000	usd
CY2021Q4	us-gaap	Retained Earnings Accumulated Deficit RetainedEarningsAccumulatedDeficit	-119646000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48753000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	79823000	usd
CY2022Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	60830000	usd
CY2021Q4	us-gaap	Liabilities And Stockholders Equity LiabilitiesAndStockholdersEquity	105346000	usd
CY2022	us-gaap	Revenues Revenues	3517000	usd
CY2021	us-gaap	Revenues Revenues	2249000	usd
CY2020	us-gaap	Revenues Revenues	332000	usd
CY2022	us-gaap	Cost Of Revenue CostOfRevenue	1283000	usd
CY2021	us-gaap	Cost Of Revenue CostOfRevenue	1440000	usd
CY2020	us-gaap	Cost Of Revenue CostOfRevenue	340000	usd
CY2022	us-gaap	Gross Profit GrossProfit	2234000	usd
CY2021	us-gaap	Gross Profit GrossProfit	809000	usd
CY2020	us-gaap	Gross Profit GrossProfit	-8000	usd
CY2022	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	36731000	usd
CY2021	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	28564000	usd
CY2020	us-gaap	Research And Development Expense ResearchAndDevelopmentExpense	12794000	usd
CY2022	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	4621000	usd
CY2021	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1814000	usd
CY2020	us-gaap	Selling And Marketing Expense SellingAndMarketingExpense	1063000	usd
CY2022	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	8613000	usd
CY2021	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	3709000	usd
CY2020	us-gaap	General And Administrative Expense GeneralAndAdministrativeExpense	1093000	usd
CY2022	us-gaap	Operating Expenses OperatingExpenses	49965000	usd
CY2021	us-gaap	Operating Expenses OperatingExpenses	34087000	usd
CY2020	us-gaap	Operating Expenses OperatingExpenses	14950000	usd
CY2022	us-gaap	Operating Income Loss OperatingIncomeLoss	-47731000	usd
CY2021	us-gaap	Operating Income Loss OperatingIncomeLoss	-33278000	usd
CY2020	us-gaap	Operating Income Loss OperatingIncomeLoss	-14958000	usd
CY2022	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	7237000	usd
CY2021	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-24814000	usd
CY2020	us-gaap	Other Operating Income Expense Net OtherOperatingIncomeExpenseNet	-667000	usd
CY2022	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-40494000	usd
CY2021	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-58092000	usd
CY2020	us-gaap	Income Loss Attributable To Parent IncomeLossAttributableToParent	-15625000	usd
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.64
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.7
CY2022	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	68489983	shares
CY2021	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	22027292	shares
CY2020	us-gaap	Weighted Average Number Of Shares Outstanding Basic WeightedAverageNumberOfSharesOutstandingBasic	9205169	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.8
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.64
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.7
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60960641	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22027292	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9205169	shares
CY2019Q4	us-gaap	Stockholders Equity StockholdersEquity	-45053000	usd
CY2020	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	439000	usd
CY2020	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	52000	usd
CY2020	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	30000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15625000	usd
CY2020Q4	us-gaap	Stockholders Equity StockholdersEquity	-60157000	usd
CY2021	arbe	Conversion Of Preferred Shares Into Ordinary Shares ConversionOfPreferredSharesIntoOrdinaryShares	63467000	usd
CY2021	arbe	Conversion Of Convertible Loan To Ordinary Shares ConversionOfConvertibleLoanToOrdinaryShares	30844000	usd
CY2021	us-gaap	Stock Issued During Period Value New Issues StockIssuedDuringPeriodValueNewIssues	91990000	usd
CY2021	arbe	Exercise Of Warrants ExerciseOfWarrants	9222000	usd
CY2021	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	2211000	usd
CY2021	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	115000	usd
CY2021	us-gaap	Stock Issued During Period Value Stock Options Exercised StockIssuedDuringPeriodValueStockOptionsExercised	223000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58092000	usd
CY2021Q4	us-gaap	Stockholders Equity StockholdersEquity	79823000	usd
CY2022	us-gaap	Stock Issued During Period Value Share Based Compensation StockIssuedDuringPeriodValueShareBasedCompensation	8793000	usd
CY2022	us-gaap	Stock Issued During Period Value Issued For Services StockIssuedDuringPeriodValueIssuedForServices	354000	usd
CY2022	us-gaap	Stock Issued During Period Value Restricted Stock Award Gross StockIssuedDuringPeriodValueRestrictedStockAwardGross	277000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-40494000	usd
CY2022Q4	us-gaap	Stockholders Equity StockholdersEquity	48753000	usd
CY2022	us-gaap	Net Income Loss NetIncomeLoss	-40494000	usd
CY2021	us-gaap	Net Income Loss NetIncomeLoss	-58092000	usd
CY2020	us-gaap	Net Income Loss NetIncomeLoss	-15625000	usd
CY2022	us-gaap	Depreciation Depreciation	481000	usd
CY2021	us-gaap	Depreciation Depreciation	342000	usd
CY2020	us-gaap	Depreciation Depreciation	228000	usd
CY2022	us-gaap	Share Based Compensation ShareBasedCompensation	8793000	usd
CY2021	us-gaap	Share Based Compensation ShareBasedCompensation	2211000	usd
CY2020	us-gaap	Share Based Compensation ShareBasedCompensation	439000	usd
CY2022	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	354000	usd
CY2021	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	115000	usd
CY2020	us-gaap	Issuance Of Stock And Warrants For Services Or Claims IssuanceOfStockAndWarrantsForServicesOrClaims	52000	usd
CY2022	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	-8122000	usd
CY2021	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	6599000	usd
CY2020	us-gaap	Adjustment Of Warrants Granted For Services AdjustmentOfWarrantsGrantedForServices	1106000	usd
CY2021	arbe	Revaluation Of Convertible Loan RevaluationOfConvertibleLoan	17866000	usd
CY2022	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	2015000	usd
CY2021	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	50000	usd
CY2020	us-gaap	Increase Decrease In Receivables IncreaseDecreaseInReceivables	137000	usd
CY2022	arbe	Decreaseincrease In Prepaid Expenses And Other Receivables DecreaseincreaseInPrepaidExpensesAndOtherReceivables	1219000	usd
CY2021	arbe	Decreaseincrease In Prepaid Expenses And Other Receivables DecreaseincreaseInPrepaidExpensesAndOtherReceivables	-2228000	usd
CY2020	arbe	Decreaseincrease In Prepaid Expenses And Other Receivables DecreaseincreaseInPrepaidExpensesAndOtherReceivables	-371000	usd
CY2022	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities	84000	usd
CY2022	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-769000	usd
CY2021	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	458000	usd
CY2020	us-gaap	Increase Decrease In Accounts Payable Trade IncreaseDecreaseInAccountsPayableTrade	-1063000	usd
CY2022	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	-234000	usd
CY2021	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	1557000	usd
CY2020	us-gaap	Increase Decrease In Employee Related Liabilities IncreaseDecreaseInEmployeeRelatedLiabilities	367000	usd
CY2022	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	-375000	usd
CY2021	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	445000	usd
CY2020	us-gaap	Increase Decrease In Deferred Revenue IncreaseDecreaseInDeferredRevenue	75000	usd
CY2022	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	884000	usd
CY2021	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	4361000	usd
CY2020	us-gaap	Increase Decrease In Other Accounts Payable And Accrued Liabilities IncreaseDecreaseInOtherAccountsPayableAndAccruedLiabilities	-356000	usd
CY2022	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-40362000	usd
CY2021	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-26416000	usd
CY2020	us-gaap	Net Cash Provided By Used In Operating Activities NetCashProvidedByUsedInOperatingActivities	-15285000	usd
CY2022	arbe	Change In Bank Deposits ChangeInBankDeposits	-400000	usd
CY2021	arbe	Change In Bank Deposits ChangeInBankDeposits	100000	usd
CY2020	arbe	Change In Bank Deposits ChangeInBankDeposits	9860000	usd
CY2022	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	918000	usd
CY2021	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	784000	usd
CY2020	us-gaap	Payments To Acquire Other Property Plant And Equipment PaymentsToAcquireOtherPropertyPlantAndEquipment	156000	usd
CY2022	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-1318000	usd
CY2021	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	-684000	usd
CY2020	us-gaap	Net Cash Provided By Used In Investing Activities NetCashProvidedByUsedInInvestingActivities	9704000	usd
CY2021	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt	4715000	usd
CY2021	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	2639000	usd
CY2020	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt	1585000	usd
CY2020	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock	1190000	usd
CY2021	arbe	Proceeds From Recapitalization And Pipe Offering Net Of Issuance Costs ProceedsFromRecapitalizationAndPIPEOfferingNetOfIssuanceCosts	98587000	usd
CY2022	us-gaap	Repayments Of Short Term Debt RepaymentsOfShortTermDebt	5218000	usd
CY2021	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	12859000	usd
CY2020	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises	256000	usd
CY2022	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	277000	usd
CY2021	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	223000	usd
CY2020	us-gaap	Proceeds From Stock Options Exercised ProceedsFromStockOptionsExercised	30000	usd
CY2021	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	11337000	usd
CY2020	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt	1641000	usd
CY2022	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	-4941000	usd
CY2021	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	125082000	usd
CY2020	us-gaap	Net Cash Provided By Used In Financing Activities NetCashProvidedByUsedInFinancingActivities	1532000	usd
CY2022	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	-1189000	usd
CY2022	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-45432000	usd
CY2021	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	97982000	usd
CY2020	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect	-4049000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100936000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2954000	usd
CY2019Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	7003000	usd
CY2022Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	54315000	usd
CY2021Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	100936000	usd
CY2020Q4	us-gaap	Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents	2954000	usd
CY2021	arbe	Exercise Of Warrants Into Convertible Preferred Shares ExerciseOfWarrantsIntoConvertiblePreferredShares	4389000	usd
CY2020	arbe	Exercise Of Warrants Into Convertible Preferred Shares ExerciseOfWarrantsIntoConvertiblePreferredShares	85000	usd
CY2021	arbe	Issuance Of Private Warrants IssuanceOfPrivateWarrants	6598000	usd
CY2021	arbe	Conversion Of Convertible Loan Into Ordinary Shares Upon The Recapitalization ConversionOfConvertibleLoanIntoOrdinarySharesUponTheRecapitalization	30844000	usd
CY2021	arbe	Conversion Of Preferred Shares Into Ordinary Shares Upon The Recapitalization ConversionOfPreferredSharesIntoOrdinarySharesUponTheRecapitalization	63467000	usd
CY2022	arbe	Purchase Of Property And Equipment1 PurchaseOfPropertyAndEquipment1	-7000	usd
CY2021	arbe	Purchase Of Property And Equipment1 PurchaseOfPropertyAndEquipment1	-340000	usd
CY2022Q4	us-gaap	Common Stock Other Shares Outstanding CommonStockOtherSharesOutstanding	48268611	shares
CY2022	us-gaap	Payments Of Ordinary Dividends PaymentsOfOrdinaryDividends	525000000	usd
CY2022Q4	us-gaap	Shares Issued Price Per Share SharesIssuedPricePerShare	10
CY2022	us-gaap	Use Of Estimates UseOfEstimates	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 0.25in">b.</td><td style="text-align: justify">Use of estimates:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The preparation of consolidated financial statements in conformity with GAAP requires management to make estimates and assumptions that affect the reported amounts of assets and liabilities and disclosure of contingent assets and liabilities at the date of the consolidated financial statements and the reported amounts of revenues and expenses during the reporting period. Significant items subject to such estimates and assumptions including fair value of warrants, share-based compensation and the underlying fair value of the Company’s ordinary shares prior to the merger.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">The Company bases these estimates on historical and anticipated results, trends and various other assumptions that it believes are reasonable under the circumstances, including assumptions as to future events. Actual results could differ from those estimates.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"> </p>
CY2022	us-gaap	Concentration Risk Credit Risk ConcentrationRiskCreditRisk	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt" width="100%"><tr style="vertical-align: top"> <td style="width: 0.25in"/><td style="width: 0.25in">d.</td><td style="text-align: justify">Concentration of risk:</td></tr></table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0in"> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0in">Most of the Company’s cash and cash equivalents, restricted cash and short-term deposits were deposited with Israeli banks and were comprised mainly of cash deposits and short-term deposits.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.75in; text-align: justify; text-indent: 0.6pt; "> </p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: 0.6pt; ">The Company’s trade receivables are derived from customers located globally. The Company mitigates its credit risks by performing credit evaluations of its customers’ financial conditions and requires customer advance payments in certain circumstances. The Company generally does not require collateral.</p><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"> </p>
CY2022Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	319000	usd
CY2022	srt	Savings Deposit Liabilities Average Rate Paid SavingsDepositLiabilitiesAverageRatePaid	0.0833	pure
CY2022	us-gaap	Severance Costs1 SeveranceCosts1	1240000	usd
CY2021	us-gaap	Severance Costs1 SeveranceCosts1	826000	usd
CY2020	us-gaap	Severance Costs1 SeveranceCosts1	466000	usd
CY2021Q4	us-gaap	Grants Receivable Current GrantsReceivableCurrent	305000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation Tax Settlements EffectiveIncomeTaxRateReconciliationTaxSettlements	0.50	pure
CY2022Q4	arbe	Government Authorities GovernmentAuthorities	280000	usd
CY2022	us-gaap	Business Combination Integration Related Costs BusinessCombinationIntegrationRelatedCosts	16707000	usd
CY2021	us-gaap	Other Income OtherIncome	83000	usd
CY2021	arbe	Other Of Revenue OtherOfRevenue	0.037	pure
CY2022	us-gaap	Revenues Revenues	3517000	usd
CY2022	arbe	Revenue Revenue	1	pure
CY2021	us-gaap	Revenues Revenues	2249000	usd
CY2021	arbe	Revenue Revenue	1	pure
CY2020	us-gaap	Deferred Revenue Additions DeferredRevenueAdditions	332000	usd
CY2021	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	726000	usd
CY2022	us-gaap	Deferred Revenue Revenue Recognized1 DeferredRevenueRevenueRecognized1	375000	usd
CY2022Q4	us-gaap	Deferred Revenue DeferredRevenue	351000	usd
CY2021Q4	us-gaap	Deferred Revenue DeferredRevenue	726000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation RevenueRemainingPerformanceObligation	232000	usd
CY2021Q4	arbe	Government Authorities GovernmentAuthorities	276000	usd
CY2022Q4	us-gaap	Deposits Deposits	85000	usd
CY2021Q4	us-gaap	Deposits Deposits	75000	usd
CY2022Q4	us-gaap	Revenue Remaining Performance Obligation Percentage RevenueRemainingPerformanceObligationPercentage	0.04	pure
CY2022	arbe	Grants Received GrantsReceived	1	pure
CY2022Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	1155000	usd
CY2021Q4	us-gaap	Prepaid Expense And Other Assets PrepaidExpenseAndOtherAssets	2402000	usd
CY2022Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	1839000	usd
CY2021Q4	us-gaap	Prepaid Expense Current And Noncurrent PrepaidExpenseCurrentAndNoncurrent	3058000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	3055000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Gross PropertyPlantAndEquipmentGross	2130000	usd
CY2022Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	1446000	usd
CY2021Q4	us-gaap	Accumulated Depreciation Depletion And Amortization Property Plant And Equipment AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment	965000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Owned Net PropertyPlantAndEquipmentOwnedNet	1609000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Owned Net PropertyPlantAndEquipmentOwnedNet	1165000	usd
CY2022	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	481000	usd
CY2021	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	342000	usd
CY2020	us-gaap	Other Depreciation And Amortization OtherDepreciationAndAmortization	228000	usd
CY2021Q3	us-gaap	Shortterm Debt Maximum Amount Outstanding During Period ShorttermDebtMaximumAmountOutstandingDuringPeriod	10000000	usd
CY2021Q3	us-gaap	Shortterm Debt Maximum Monthend Outstanding Amount ShorttermDebtMaximumMonthendOutstandingAmount	5000000	usd
CY2022Q4	us-gaap	Short Term Debt Percentage Bearing Fixed Interest Rate ShortTermDebtPercentageBearingFixedInterestRate	0.10	pure
CY2022	us-gaap	Debt Instrument Maturity Date DebtInstrumentMaturityDate	2022-07-01
CY2022	us-gaap	Line Of Credit Facility Commitment Fee Amount LineOfCreditFacilityCommitmentFeeAmount	250000	usd
CY2022	us-gaap	Line Of Credit Facility Commitment Fee Percentage LineOfCreditFacilityCommitmentFeePercentage	0.04	pure
CY2022Q2	us-gaap	Interest Expense Short Term Borrowings InterestExpenseShortTermBorrowings	200000	usd
CY2022	us-gaap	Operating Lease Payments OperatingLeasePayments	370000	usd
CY2021	us-gaap	Operating Lease Payments OperatingLeasePayments	245000	usd
CY2022	us-gaap	Right Of Use Asset Obtained In Exchange For Operating Lease Liability RightOfUseAssetObtainedInExchangeForOperatingLeaseLiability	84000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Next Twelve Months LesseeOperatingLeaseLiabilityPaymentsDueNextTwelveMonths	366000	usd
CY2022Q4	us-gaap	Lessee Operating Lease Liability Payments Due Year Two LesseeOperatingLeaseLiabilityPaymentsDueYearTwo	32000	usd
CY2022Q4	us-gaap	Operating Leases Future Minimum Payments Due OperatingLeasesFutureMinimumPaymentsDue	398000	usd
CY2022Q4	us-gaap	Unrecorded Unconditional Purchase Obligation Imputed Interest UnrecordedUnconditionalPurchaseObligationImputedInterest	17000	usd
CY2022Q4	us-gaap	Operating Lease Liability OperatingLeaseLiability	381000	usd
CY2022Q4	us-gaap	Operating Lease Right Of Use Asset OperatingLeaseRightOfUseAsset	465000	usd
CY2022	arbe	Current Maturities Of Operating Leases CurrentMaturitiesOfOperatingLeases	364000	usd
CY2022Q4	us-gaap	Long Term Debt And Capital Lease Obligations Current LongTermDebtAndCapitalLeaseObligationsCurrent	17000	usd
CY2022Q4	us-gaap	Operating Lease Weighted Average Remaining Lease Term1 OperatingLeaseWeightedAverageRemainingLeaseTerm1	P1Y1M6D
CY2022Q4	us-gaap	Operating Lease Weighted Average Discount Rate Percent OperatingLeaseWeightedAverageDiscountRatePercent	0.058	pure
CY2022Q4	us-gaap	Fair Value Option Ineligible Items Aggregate Carrying Amount FairValueOptionIneligibleItemsAggregateCarryingAmount	3729000	usd
CY2020Q4	us-gaap	Convertible Debt ConvertibleDebt	1641000	usd
CY2021Q1	us-gaap	Investments In And Advances To Affiliates At Fair Value Gross Additions InvestmentsInAndAdvancesToAffiliatesAtFairValueGrossAdditions	12978000	usd
CY2022	us-gaap	Recapitalization Costs RecapitalizationCosts	30840000	usd
CY2022	us-gaap	Conversion Of Stock Shares Converted1 ConversionOfStockSharesConverted1	3205020	shares
CY2019Q4	us-gaap	Additional Collateral Aggregate Fair Value AdditionalCollateralAggregateFairValue	550000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Weighted Average Volatility Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsWeightedAverageVolatilityRate	0.05	pure
CY2022	us-gaap	Fair Value Adjustment Of Warrants FairValueAdjustmentOfWarrants	360	usd
CY2022Q4	us-gaap	Environmental Costs Recognized Capitalized EnvironmentalCostsRecognizedCapitalized	8425000	usd
CY2021Q4	us-gaap	Environmental Costs Recognized Capitalized EnvironmentalCostsRecognizedCapitalized	3083000	usd
CY2020Q4	us-gaap	Environmental Costs Recognized Capitalized EnvironmentalCostsRecognizedCapitalized	235000	usd
CY2022Q4	arbe	Ordinary Shares Per Value OrdinarySharesPerValue	0.000216
CY2022	arbe	Plan Expiration Period PlanExpirationPeriod	P7Y
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Options Vested And Expected To Vest Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1	P4Y
CY2019Q4	arbe	Options Outstanding Outstanding Share Options Beginning Balance OptionsOutstandingOutstandingShareOptionsBeginningBalance	3555804	shares
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.652
CY2020	arbe	Sharebased Compensation Arrangement By Sharebased Payment Award Options Outstanding Weighted Average Remaining Contractual Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm1	P5Y8D
CY2019Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	109779000	usd
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	932835	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	1.199
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	494450	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	1.042
CY2020	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	226155	shares
CY2020	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.132
CY2020Q4	arbe	Options Outstanding Outstanding Share Options Beginning Balance OptionsOutstandingOutstandingShareOptionsBeginningBalance	3768034	shares
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	0.767
CY2020	arbe	Options Outstanding Weighted Average Remaining Contractual Lifeyears Ending Balance OptionsOutstandingWeightedAverageRemainingContractualLifeyearsEndingBalance	P4Y7M15D
CY2020Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	119146000	usd
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1966916	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	7.25
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	117863	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	0.972
CY2021	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	155750	shares
CY2021	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.602
CY2021Q4	arbe	Options Outstanding Outstanding Share Options Beginning Balance OptionsOutstandingOutstandingShareOptionsBeginningBalance	5461337	shares
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	3.102
CY2021	arbe	Options Outstanding Weighted Average Remaining Contractual Lifeyears Ending Balance OptionsOutstandingWeightedAverageRemainingContractualLifeyearsEndingBalance	P5Y4M10D
CY2021Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	16713971000	usd
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Grants In Period Gross ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross	1630142	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Grants In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice	6.833
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Forfeitures And Expirations In Period ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresAndExpirationsInPeriod	468814	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Forfeitures In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice	5.557
CY2022	us-gaap	Stock Issued During Period Shares Stock Options Exercised StockIssuedDuringPeriodSharesStockOptionsExercised	570451	shares
CY2022	us-gaap	Share Based Compensation Arrangements By Share Based Payment Award Options Exercises In Period Weighted Average Exercise Price ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsExercisesInPeriodWeightedAverageExercisePrice	0.482
CY2022Q4	arbe	Options Outstanding Outstanding Share Options Beginning Balance OptionsOutstandingOutstandingShareOptionsBeginningBalance	6052214	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice	4.166
CY2022	arbe	Options Outstanding Weighted Average Remaining Contractual Lifeyears Ending Balance OptionsOutstandingWeightedAverageRemainingContractualLifeyearsEndingBalance	P5Y6M25D
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Outstanding Intrinsic Value ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue	7761705000	usd
CY2022	arbe	Exercisable Outstanding Share Options ExercisableOutstandingShareOptions	3322177	shares
CY2022Q4	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Options Vested And Expected To Vest Exercisable Weighted Average Exercise Price ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestExercisableWeightedAverageExercisePrice	2.073
CY2022	arbe	Exercisable Weighted Average Remaining Contractual Lifeyears ExercisableWeightedAverageRemainingContractualLifeyears	P3Y7M
CY2022	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Equity Instruments Other Than Options Aggregate Intrinsic Value Vested SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueVested	7039511000	usd
CY2022	arbe	Share Based Compensation Arrangement By Share Based Payment Award Options Options Available For Future Grants ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOptionsAvailableForFutureGrants	1423623	shares
CY2020	us-gaap	Sharebased Compensation Arrangement By Sharebased Payment Award Fair Value Assumptions Expected Term1 SharebasedCompensationArrangementBySharebasedPaymentAwardFairValueAssumptionsExpectedTerm1	P4Y7M9D
CY2022	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2021	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2020	us-gaap	Share Based Compensation Arrangement By Share Based Payment Award Fair Value Assumptions Expected Dividend Rate ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedDividendRate	0	pure
CY2022	us-gaap	Share Based Goods And Nonemployee Services Transaction Valuation Method Expected Dividend Rate ShareBasedGoodsAndNonemployeeServicesTransactionValuationMethodExpectedDividendRate	0	pure
CY2022	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	5726000	usd
CY2021	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	1518000	usd
CY2020	us-gaap	Other Research And Development Expense OtherResearchAndDevelopmentExpense	320000	usd
CY2022	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	1403000	usd
CY2021	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	217000	usd
CY2020	us-gaap	Other Selling And Marketing Expense OtherSellingAndMarketingExpense	65000	usd
CY2022	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	1537000	usd
CY2021	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	419000	usd
CY2020	us-gaap	Other General And Administrative Expense OtherGeneralAndAdministrativeExpense	46000	usd
CY2022	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	127000	usd
CY2021	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	57000	usd
CY2020	us-gaap	Other Cost Of Operating Revenue OtherCostOfOperatingRevenue	8000	usd
CY2022	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	8793000	usd
CY2021	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	2211000	usd
CY2020	us-gaap	Allocated Share Based Compensation Expense AllocatedShareBasedCompensationExpense	439000	usd
CY2022	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-40494000	usd
CY2021	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-58092000	usd
CY2020	us-gaap	Net Income Loss Attributable To Nonredeemable Noncontrolling Interest NetIncomeLossAttributableToNonredeemableNoncontrollingInterest	-15625000	usd
CY2022	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	63489983	shares
CY2021	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	22027292	shares
CY2020	us-gaap	Weighted Average Number Diluted Shares Outstanding Adjustment WeightedAverageNumberDilutedSharesOutstandingAdjustment	9205169	shares
CY2022	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-0.64
CY2021	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-2.64
CY2020	us-gaap	Earnings Per Share Basic EarningsPerShareBasic	-1.7
CY2022	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-48919000	usd
CY2021	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-58092000	usd
CY2020	us-gaap	Temporary Equity Accretion To Redemption Value Adjustment TemporaryEquityAccretionToRedemptionValueAdjustment	-15625000	usd
CY2022	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	60960641	shares
CY2021	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	22027292	shares
CY2020	us-gaap	Weighted Average Number Of Diluted Shares Outstanding WeightedAverageNumberOfDilutedSharesOutstanding	9205169	shares
CY2022	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-0.8
CY2021	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-2.64
CY2020	us-gaap	Earnings Per Share Diluted EarningsPerShareDiluted	-1.7
CY2022	arbe	Schedule Of Loss Per Share Attributable To Ordinary Shareholders ScheduleOfLossPerShareAttributableToOrdinaryShareholders	<table cellpadding="0" cellspacing="0" style="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse"> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="border-bottom: black 1.5pt solid; text-align: center"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt"><b>December 31,<br/> 2022</b></span></td> <td> </td></tr> <tr style="vertical-align: bottom"> <td> </td> <td> </td> <td colspan="2" style="text-align: center"> </td> <td> </td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td style="width: 89%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Net loss</span></td> <td style="width: 1%"> </td> <td style="width: 1%"> </td> <td style="width: 8%; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(40,494</span></td> <td style="width: 1%"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Revaluation of warrants</span></td> <td> </td> <td style="border-bottom: black 1.5pt solid"> </td> <td style="border-bottom: black 1.5pt solid; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(8,425</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> <tr style="vertical-align: bottom; background-color: #CCEEFF"> <td> </td> <td> </td> <td> </td> <td style="text-align: right"> </td> <td> </td></tr> <tr style="vertical-align: bottom; "> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">Adjusted Net loss</span></td> <td> </td> <td style="border-bottom: black 4.5pt double"> </td> <td style="border-bottom: black 4.5pt double; text-align: right"><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">(48,919</span></td> <td><span style="font-family: Times New Roman, Times, Serif; font-size: 10pt">)</span></td></tr> </table><p style="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0 0pt 0.5in; text-align: justify; text-indent: -0.5in"><span style="font-weight: normal"> </span></p>
CY2022	us-gaap	Net Income Loss Available To Common Stockholders Basic NetIncomeLossAvailableToCommonStockholdersBasic	-40494000	usd
CY2022	us-gaap	Proceeds From Issuance Of Warrants ProceedsFromIssuanceOfWarrants	8425000	usd
CY2022	us-gaap	Temporary Equity Net Income TemporaryEquityNetIncome	-48919000	usd
CY2021Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	26499069	shares
CY2020Q4	us-gaap	Convertible Preferred Stock Shares Issued Upon Conversion ConvertiblePreferredStockSharesIssuedUponConversion	33729498	shares
CY2022	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	8650298	shares
CY2021	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1362786	shares
CY2020	us-gaap	Antidilutive Securities Excluded From Computation Of Earnings Per Share Amount AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount	1656585	shares
CY2022	arbe	Total Total	8650298	shares
CY2021	arbe	Total Total	27861855	shares
CY2020	arbe	Total Total	35386083	shares
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-40494000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-58092000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Domestic IncomeLossFromContinuingOperationsBeforeIncomeTaxesDomestic	-15625000	usd
CY2022	arbe	Income Loss From Continuing Operation Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-40494000	usd
CY2021	arbe	Income Loss From Continuing Operation Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-58092000	usd
CY2020	arbe	Income Loss From Continuing Operation Before Income Taxes Minority Interest And Income Loss From Equity Method Investments IncomeLossFromContinuingOperationBeforeIncomeTaxesMinorityInterestAndIncomeLossFromEquityMethodInvestments	-15625000	usd
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	40494000	usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	58092000	usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest	15625000	usd
CY2022	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2021	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2020	us-gaap	Effective Income Tax Rate Reconciliation At Federal Statutory Income Tax Rate EffectiveIncomeTaxRateReconciliationAtFederalStatutoryIncomeTaxRate	0.23	pure
CY2022	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-9314000	usd
CY2021	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-13361000	usd
CY2020	us-gaap	Income Tax Reconciliation Income Tax Expense Benefit At Federal Statutory Income Tax Rate IncomeTaxReconciliationIncomeTaxExpenseBenefitAtFederalStatutoryIncomeTaxRate	-3594000	usd
CY2022	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	475000	usd
CY2021	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	6129000	usd
CY2020	us-gaap	Income Tax Reconciliation Nondeductible Expense IncomeTaxReconciliationNondeductibleExpense	371000	usd
CY2022	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	3517000	usd
CY2021	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	209000	usd
CY2020	us-gaap	Income Tax Reconciliation Foreign Income Tax Rate Differential IncomeTaxReconciliationForeignIncomeTaxRateDifferential	-1093000	usd
CY2022	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	5322000	usd
CY2021	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	7023000	usd
CY2020	us-gaap	Income Tax Reconciliation Change In Deferred Tax Assets Valuation Allowance IncomeTaxReconciliationChangeInDeferredTaxAssetsValuationAllowance	4316000	usd
CY2022Q4	us-gaap	Operating Loss Carryforwards OperatingLossCarryforwards	95612	usd
CY2022Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	27154000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Net DeferredTaxAssetsNet	21832000	usd
CY2022Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	27154000	usd
CY2021Q4	us-gaap	Deferred Tax Assets Valuation Allowance DeferredTaxAssetsValuationAllowance	21832000	usd
CY2022Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	1609000	usd
CY2021Q4	us-gaap	Property Plant And Equipment Other Net PropertyPlantAndEquipmentOtherNet	1165000	usd
CY2022Q4	us-gaap	Short Term Borrowings ShortTermBorrowings		usd
CY2020	arbe	Issuance Of Redeemable Convertible Preferred Shares IssuanceOfRedeemableConvertiblePreferredShares		usd
CY2020	arbe	Exercise And Conversion Of Warrants ExerciseAndConversionOfWarrants		usd
CY2022	arbe	Revaluation Of Convertible Loan RevaluationOfConvertibleLoan		usd
CY2020	arbe	Revaluation Of Convertible Loan RevaluationOfConvertibleLoan		usd
CY2021	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities		usd
CY2020	us-gaap	Increase Decrease In Derivative Assets And Liabilities IncreaseDecreaseInDerivativeAssetsAndLiabilities		usd
CY2022	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2020	us-gaap	Proceeds From Short Term Debt ProceedsFromShortTermDebt		usd
CY2022	us-gaap	Repayments Of Long Term Debt RepaymentsOfLongTermDebt		usd
CY2022	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2021	us-gaap	Proceeds From Issuance Of Convertible Preferred Stock ProceedsFromIssuanceOfConvertiblePreferredStock		usd
CY2022	arbe	Proceeds From Recapitalization And Pipe Offering Net Of Issuance Costs ProceedsFromRecapitalizationAndPIPEOfferingNetOfIssuanceCosts		usd
CY2020	arbe	Proceeds From Recapitalization And Pipe Offering Net Of Issuance Costs ProceedsFromRecapitalizationAndPIPEOfferingNetOfIssuanceCosts		usd
CY2022	us-gaap	Proceeds From Warrant Exercises ProceedsFromWarrantExercises		usd
CY2022	us-gaap	Proceeds From Convertible Debt ProceedsFromConvertibleDebt		usd
CY2021	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2020	us-gaap	Effect Of Exchange Rate On Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents		usd
CY2022	arbe	Exercise Of Warrants Into Convertible Preferred Shares ExerciseOfWarrantsIntoConvertiblePreferredShares		usd
CY2022	arbe	Issuance Of Private Warrants IssuanceOfPrivateWarrants		usd
CY2020	arbe	Issuance Of Private Warrants IssuanceOfPrivateWarrants		usd
CY2022	arbe	Conversion Of Convertible Loan Into Ordinary Shares Upon The Recapitalization ConversionOfConvertibleLoanIntoOrdinarySharesUponTheRecapitalization		usd
CY2020	arbe	Conversion Of Convertible Loan Into Ordinary Shares Upon The Recapitalization ConversionOfConvertibleLoanIntoOrdinarySharesUponTheRecapitalization		usd
CY2022	arbe	Conversion Of Preferred Shares Into Ordinary Shares Upon The Recapitalization ConversionOfPreferredSharesIntoOrdinarySharesUponTheRecapitalization		usd
CY2020	arbe	Conversion Of Preferred Shares Into Ordinary Shares Upon The Recapitalization ConversionOfPreferredSharesIntoOrdinarySharesUponTheRecapitalization		usd
CY2020	arbe	Purchase Of Property And Equipment1 PurchaseOfPropertyAndEquipment1		usd
CY2022	us-gaap	Other Income OtherIncome		usd
CY2022	arbe	Other Of Revenue OtherOfRevenue		pure
CY2022	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2021	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2020	us-gaap	Income Loss From Continuing Operations Before Income Taxes Foreign IncomeLossFromContinuingOperationsBeforeIncomeTaxesForeign		usd
CY2022	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2021	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2020	us-gaap	Income Tax Expense Benefit IncomeTaxExpenseBenefit		usd
CY2022Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2021Q4	us-gaap	Deferred Tax Assets Liabilities Net DeferredTaxAssetsLiabilitiesNet		usd
CY2022	dei	Amendment Flag AmendmentFlag	false
CY2022	dei	Document Fiscal Period Focus DocumentFiscalPeriodFocus	FY
CY2022	dei	Entity Address Postal Zip Code EntityAddressPostalZipCode	6329302
CY2022	dei	Entity Central Index Key EntityCentralIndexKey	0001861841

Files In Submission

Name	View Source	Status
0001213900-23-022143-index-headers.html	Edgar Link	pending
0001213900-23-022143-index.html	Edgar Link	pending
0001213900-23-022143.txt	Edgar Link	pending
0001213900-23-022143-xbrl.zip	Edgar Link	pending
arbe-20221231.xsd	Edgar Link	pending
f20f2022ex12-1_arberobotics.htm	Edgar Link	pending
f20f2022ex12-2_arberobotics.htm	Edgar Link	pending
f20f2022ex13-1_arberobotics.htm	Edgar Link	pending
f20f2022ex19-1_arberobotics.htm	Edgar Link	pending
f20f2022ex23-1_arberobotics.htm	Edgar Link	pending
f20f2022_arberoboticsltd.htm	Edgar Link	pending
Financial_Report.xlsx	Edgar Link	pending
fin_001.jpg	Edgar Link	pending
image_001.jpg	Edgar Link	pending
image_002.jpg	Edgar Link	pending
image_003.jpg	Edgar Link	pending
image_004.jpg	Edgar Link	pending
image_005.jpg	Edgar Link	pending
image_006.jpg	Edgar Link	pending
image_007.jpg	Edgar Link	pending
MetaLinks.json	Edgar Link	pending
R1.htm	Edgar Link	pending
R10.htm	Edgar Link	pending
R11.htm	Edgar Link	pending
R12.htm	Edgar Link	pending
R13.htm	Edgar Link	pending
R14.htm	Edgar Link	pending
R15.htm	Edgar Link	pending
R16.htm	Edgar Link	pending
R17.htm	Edgar Link	pending
R18.htm	Edgar Link	pending
R19.htm	Edgar Link	pending
R2.htm	Edgar Link	pending
R20.htm	Edgar Link	pending
R21.htm	Edgar Link	pending
R22.htm	Edgar Link	pending
R23.htm	Edgar Link	pending
R24.htm	Edgar Link	pending
R25.htm	Edgar Link	pending
R26.htm	Edgar Link	pending
arbe-20221231_cal.xml	Edgar Link	unprocessable
arbe-20221231_def.xml	Edgar Link	unprocessable
FilingSummary.xml	Edgar Link	unprocessable
f20f2022_arberoboticsltd_htm.xml	Edgar Link	completed
R27.htm	Edgar Link	pending
R28.htm	Edgar Link	pending
R29.htm	Edgar Link	pending
R3.htm	Edgar Link	pending
R30.htm	Edgar Link	pending
R31.htm	Edgar Link	pending
R32.htm	Edgar Link	pending
R33.htm	Edgar Link	pending
R34.htm	Edgar Link	pending
R35.htm	Edgar Link	pending
R36.htm	Edgar Link	pending
R37.htm	Edgar Link	pending
R38.htm	Edgar Link	pending
R39.htm	Edgar Link	pending
R4.htm	Edgar Link	pending
R40.htm	Edgar Link	pending
R41.htm	Edgar Link	pending
R42.htm	Edgar Link	pending
R43.htm	Edgar Link	pending
R44.htm	Edgar Link	pending
R45.htm	Edgar Link	pending
R46.htm	Edgar Link	pending
R47.htm	Edgar Link	pending
R48.htm	Edgar Link	pending
R49.htm	Edgar Link	pending
R5.htm	Edgar Link	pending
R50.htm	Edgar Link	pending
R51.htm	Edgar Link	pending
R52.htm	Edgar Link	pending
R53.htm	Edgar Link	pending
R54.htm	Edgar Link	pending
R55.htm	Edgar Link	pending
R56.htm	Edgar Link	pending
R57.htm	Edgar Link	pending
R58.htm	Edgar Link	pending
R59.htm	Edgar Link	pending
R6.htm	Edgar Link	pending
R60.htm	Edgar Link	pending
R61.htm	Edgar Link	pending
R62.htm	Edgar Link	pending
R63.htm	Edgar Link	pending
R7.htm	Edgar Link	pending
R8.htm	Edgar Link	pending
R9.htm	Edgar Link	pending
report.css	Edgar Link	pending
Show.js	Edgar Link	pending
arbe-20221231_pre.xml	Edgar Link	unprocessable
arbe-20221231_lab.xml	Edgar Link	unprocessable

Create your account

Find Stocks Worth Researching

Deeply Understand Businesses

Value Businesses Intelligently

$ARBE
Arbe Robotics Ltd. Stock $arbe

2023 Q1 Form 20-F Financial Statement

#000121390023022143 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARBE Arbe Robotics Ltd. Stock $arbe

2023 Q1 Form 20-F Financial Statement

#000121390023022143 Filed on March 22, 2023

Income Statement

Balance Sheet

Cashflow Statement

Facts In Submission

Files In Submission

$ARBE
Arbe Robotics Ltd. Stock $arbe